rosiglitazone has been researched along with Thyroid Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JY; Chi, CW; Hsu, YC; Lee, CH; Lee, HC; Wang, JJ | 1 |
| Okiyama, Y; Sakaguchi, K; Tanaka, S | 1 |
| Chan, AB; Chen, GG; Chu, R; Fan, MD; Li, XY; Liu, SY; Liu, Z; Ng, EK; Ng, SK; van Hasselt, A; Vlantis, AC | 1 |
| Tseng, CH | 1 |
| Fröhlich, E; Wahl, R | 1 |
| Andò, S; Aquila, S; Belmonte, M; Bonofiglio, D; Catalano, S; Gabriele, S; Qi, H | 1 |
| Antonelli, A; Basolo, F; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Marchetti, I; Materazzi, G; Miccoli, P; Ugolini, C | 1 |
| Honsawek, S; Keelawat, S; Ruangvejvorachai, P; Tepmongkol, S | 1 |
| Antonelli, A; Barani, L; Basolo, F; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Giannini, R; Marchetti, I; Materazzi, G; Miccoli, P; Minuto, M | 1 |
| Cambil, T; Castro, J; Martín, T; Torres, A | 1 |
| Clark, OH; Greenspan, FS; Hawkins, R; Kebebew, E; Lindsay, S; Woeber, KA | 1 |
| Bockisch, A; Freudenberg, LS; Jentzen, W; Nagarajah, J; Rosenbaum-Krumme, SJ | 1 |
| Antonelli, A; Basolo, F; Di Domenicantonio, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Galleri, D; Miccoli, P; Piaggi, S; Santarpia, L | 1 |
| Buchegger, F; Meier, CA; Petite, C; Philips, JC; Willi, JP | 1 |
| Fröhlich, E; Machicao, F; Wahl, R | 1 |
| Araki, O; Cheng, SY; Furuya, F; Kato, Y; Willingham, MC; Ying, H; Zhao, L | 1 |
| Aiello, A; Belfiore, A; Conte, E; Frasca, F; Genua, M; Murabito, A; Pandini, G; Sacco, A; Vigneri, R | 1 |
| Elias, AN; Lizotte, P | 1 |
| Clark, OH; Duh, QY; Greenspan, FS; Kebebew, E; Lindsay, S; Morita, E; Peng, M; Reiff, E; Treseler, P; Woeber, KA | 1 |
| Elias, AN; Hofflich, H; Lizotte, P | 1 |
| Endo, T; Haraguchi, K; Hershman, JM; Ohta, K; Onaya, T | 1 |
1 review(s) available for rosiglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromans; Female; Forecasting; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Pyrazoles; Pyrimidines; Risk Assessment; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Treatment Outcome; Troglitazone | 2014 |
2 trial(s) available for rosiglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Dose-Response Relationship, Drug; Female; Humans; Iodine; Iodine Radioisotopes; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Neoplasms; Whole Body Imaging | 2008 |
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
Topics: Adult; Aged; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Male; Middle Aged; PPAR gamma; Radionuclide Imaging; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms | 2006 |
18 other study(ies) available for rosiglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Topics: Bexarotene; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Humans; PPAR gamma; Retinoid X Receptors; Rosiglitazone; Symporters; Thyroid Neoplasms; Tumor Hypoxia | 2020 |
In silico modeling of PAX8-PPARγ fusion protein in thyroid carcinoma: influence of structural perturbation by fusion on ligand-binding affinity.
Topics: Antineoplastic Agents; Binding Sites; Drug Discovery; Humans; Hypoglycemic Agents; Ligands; Models, Molecular; Oncogene Proteins, Fusion; Protein Conformation; Rosiglitazone; Thermodynamics; Thyroid Neoplasms | 2021 |
The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.
Topics: Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Knockdown Techniques; Humans; PPAR gamma; Receptor Cross-Talk; Rosiglitazone; Signal Transduction; Thiazolidinediones; Thyroid Neoplasms; Transfection | 2014 |
Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Rosiglitazone; Taiwan; Thiazolidinediones; Thyroid Neoplasms; Treatment Outcome | 2013 |
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
Topics: Adenocarcinoma, Follicular; Cell Division; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Oligonucleotides, Antisense; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Signal Transduction; Sp1 Transcription Factor; Thiazolidinediones; Thyroid Neoplasms; Up-Regulation | 2008 |
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Proto-Oncogene Proteins B-raf; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Tumor Cells, Cultured | 2008 |
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.
Topics: Carcinoma; Cell Proliferation; Growth Inhibitors; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Tumor Cells, Cultured | 2009 |
[Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
Topics: Carcinoma, Papillary; Female; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Iodine Radioisotopes; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms | 2008 |
Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
Topics: Adult; Carcinoma, Papillary; Combined Modality Therapy; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms | 2009 |
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2012 |
Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.
Topics: Apoptosis; Cell Proliferation; Cell Survival; Chemokine CXCL10; Cytokines; Electrophoretic Mobility Shift Assay; Humans; Immunoblotting; Rosiglitazone; Th1 Cells; Thiazolidinediones; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms | 2012 |
Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
Topics: Adult; Aged; Cell Differentiation; Humans; Hypoglycemic Agents; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pilot Projects; Positron-Emission Tomography; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed | 2004 |
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transformed; Cell Proliferation; Chromans; Pioglitazone; PPAR gamma; Radiation-Sensitizing Agents; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Swine; Symporters; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms; Troglitazone | 2005 |
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway.
Topics: Animals; Apoptosis; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin D1; Female; Humans; Male; Mice; Mice, Mutant Strains; NF-kappa B; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Thyroid Hormone Receptors beta; Thyroid Neoplasms | 2006 |
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Caspase 3; Caspase 7; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epithelial Cells; Gene Expression; Humans; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Luciferases; Mesoderm; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retinoblastoma Protein; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Transfection | 2006 |
Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
Topics: Cell Differentiation; Female; Humans; Hypoglycemia; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Peroxisome Proliferator-Activated Receptors; Radionuclide Imaging; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Neoplasms | 2006 |
Evidence of acute pancreatitis in a patient with radioresistant-differentiated thyroid cancer.
Topics: Female; Humans; Middle Aged; Pancreatitis; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Radionuclide Imaging; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Treatment Failure | 2008 |
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma, Papillary; Cell Division; Chromans; Humans; Male; Mice; Mice, Inbred BALB C; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thymidine; Thyroid Neoplasms; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |